Global Nexus, short for Global Nexus for Pandemics and Biological Threats, is a Canadian public-private partnership based in Hamilton, Ontario. It is described as "a partnership-focused health innovation accelerator" based out of the McMaster University Faculty of Health Sciences.[1]
History
Global Nexus researchers developed an inhaled COVID-19 vaccine currently entering Phase 2 clinical trials.[2]
On April 23, 2024, Pfizer announced a $500,000 investment in Global Nexus for the training of "emerging scholars from equity-deserving groups in the field of vaccinology, as well as students conducting vaccine research focused on populations who are especially vulnerable to infectious diseases."[2:1][3]
Organization
Global Nexus is a partner organization leading the Canadian Pandemic Preparedness Hub (CP2H).[4]
Personnel
| Name | Position | Notes |
|---|---|---|
| Matthew Miller | Executive Director[2:2] | - |
Funding
Global Nexus has received funding from:
External links
Home. The Global Nexus for Pandemics & Biological Threats. Retrieved April 23, 2024, from http://archive.today/2024.04.23-200201/https://globalnexus.mcmaster.ca/ ↩︎
Pfizer Canada Inc. (2024, April 23). Pfizer Canada and McMaster University to foster health equity in vaccine science. Cision Newswire. http://archive.today/2024.04.23-183907/https://www.newswire.ca/news-releases/pfizer-canada-and-mcmaster-university-to-foster-health-equity-in-vaccine-science-861273714.html ↩︎ ↩︎ ↩︎
Advancing Equitable and Inclusive Vaccine Science. The Global Nexus for Pandemics & Biological Threats. Retrieved April 23, 2024, from http://archive.today/2024.04.23-201816/https://globalnexus.mcmaster.ca/advancing-equitable-and-inclusive-vaccine-science/ ↩︎ ↩︎
Canadian Pandemic Preparedness Hub (CP2H). University of Ottawa. Retrieved March 26, 2024, from https://web.archive.org/web/20240326071831/https://www.uottawa.ca/research-innovation/canadian-pandemic-preparedness-hub ↩︎ ↩︎
